Hi All,
Maybe some of you have seen this already, Travere have inked a new licencing deal for SE Asia (excluding China) for Sparsentan in IgAN (for which they received Accelerated Approval from the FDA for at an Interim Endpoint during that trial). For FSGS, the FDA requested more data.
Travere also signed a licencing agreement with Vifor/CSL on those Interim results for IgAN (a bit of history there).
There are multiple articles out there, but here is Travere’s press release, better to go to the horse’s mouth:
https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-announces-licensing-agreement-renalys
They need to do a Registrational Trial in Asia. I think what Nina was discussing in regards to a bridging study being waived in China for our ACTION 3 trial & now this information regarding this becomes all the more interesting & important.
While IgAN is a different kidney disease indication, our drug DMX-200 has a different MOA (mode of action) possibly even synergistic with Sparsentan if pre-clinical results are confirmed in clinical trials down the track.
I find it interesting to look at Travere’s journey as an example in the kidney disease space.
Have a great weekend all, happy reading.
- Forums
- ASX - By Stock
- DXB Media thread.
Hi All, Maybe some of you have seen this already, Travere have...
-
-
- There are more pages in this discussion • 159 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
43.5¢ |
Change
0.005(1.16%) |
Mkt cap ! $239.5M |
Open | High | Low | Value | Volume |
42.5¢ | 44.3¢ | 42.5¢ | $634.3K | 1.458M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9998 | 43.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
44.5¢ | 26920 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 108769 | 0.430 |
4 | 165895 | 0.425 |
4 | 423261 | 0.420 |
4 | 97400 | 0.415 |
5 | 170050 | 0.410 |
Price($) | Vol. | No. |
---|---|---|
0.445 | 12222 | 1 |
0.450 | 131409 | 4 |
0.455 | 118833 | 3 |
0.460 | 100000 | 3 |
0.465 | 42150 | 3 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online